Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 549/385)
  • Patent number: 10654823
    Abstract: The disclosure provides methods and compositions for providing shatter formulations taking the form of crystalline polymorphs, where methods of preparation include preparing tetrahydrocannabinol acid (THCA) powder followed by decarboxylating THCA and removal of terpenes.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 19, 2020
    Assignee: Scientific Holdings, LLC
    Inventors: Jeffrey Charles Raber, Bradley J. Douglass
  • Publication number: 20150119456
    Abstract: The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: January 17, 2013
    Publication date: April 30, 2015
    Inventors: Thomas D. Pallin, Hazel J. Dyke, Susan M. Cramp, Robert Zahler
  • Patent number: 8937097
    Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 20, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Arie L. Gutman, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
  • Publication number: 20140088078
    Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: May 7, 2012
    Publication date: March 27, 2014
    Applicant: ZAFGEN, Inc.
    Inventors: Susan Mary Cramp, Hazel Joan Dyke, Thomas David Pallin, Robert Zahler
  • Publication number: 20130203843
    Abstract: The present invention relates to biology and medicine and in particular can be used in medicine for the preparation of a pharmaceutical composition for the specific, self-regulating uncoupling of mitochondria. The invention can be useful in the treatment of diseases and conditions associated with the disruption of cellular metabolism, in the treatment of obesity, including pathological forms thereof, and also for the treatment of diseases associated with the increased formation of free radicals and reactive oxygen species.
    Type: Application
    Filed: June 24, 2010
    Publication date: August 8, 2013
    Applicant: LIMITED LIABILITY COMPANY MITOTECH
    Inventors: Vladimir Petrovich Skulachev, Maxim Vladimirovich Skulachev, Roman Alexeevich Zinovkin, Fedor Fedorovich Severin, Yury Nikolaevich Antonenko, Dmitry Borisovich Zorov, Egor Yurievich Plotnikov, Nikolay Konstantinovich Isaev, Denis Nikolaevich Silachev, Dmitry Alexeevich Knorre
  • Patent number: 8500807
    Abstract: The invention relates to an intraocular lens comprising at least one pharmaceutically-acceptable photochromic polymer that enables all or part of the intraocular lens to change colour reversibly when exposed to light.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: August 6, 2013
    Assignee: Carl Zeiss Meditec SAS
    Inventors: Pascal Bernard, Marc Dolatkhani, Anne Pagnoux, Christophe Hupin
  • Publication number: 20130197241
    Abstract: The invention provides methods for cyclizing poly-yne compounds under mild conditions to provide cyclic compounds.
    Type: Application
    Filed: January 31, 2013
    Publication date: August 1, 2013
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: REGENTS OF THE UNIVERSITY OF MINNESOTA
  • Patent number: 8309319
    Abstract: A fluorescent probe for measurement of UDP-glucuronosyltransferase, which comprises a fluorescein derivative, wherein in the fluorescein derivative, the 2-carboxy group on the benzene ring of fluorescein is replaced with another monovalent substituent, provided that said substituent is a substituent other than sulfo group, and the substituent does not have carboxy group or sulfo group, and wherein the fluorescein derivative may have an arbitrary substituent at a position on the benzene ring other than the 2-position, and the fluorescein derivative may have a substituent selected from the group consisting of an alkoxy group and a halogen atom at the 2-position and/or the 7-position of fluorescein.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: November 13, 2012
    Assignee: The University of Tokyo
    Inventors: Tetsuo Nagano, Yasuteru Urano, Rie Tomiyasu
  • Patent number: 8158329
    Abstract: The present invention provides a compound represented by the formula (I): wherein P1, P2, P3, P4 and P5 each independently represents a hydrogen atom etc., and at least one selected from the group consisting of R1, R2, R3, R4, R5, R6, R7, R8 and R9 is the group represented by the formula (II): wherein X1 and X2 each independently represent a hydrogen atom etc., n represents an integer of 1 to 4, Z1 represents a C1-C6 alkyl group etc., and ring Y represents an alicyclic hydrocarbon group, and the others each independently represent a hydrogen atom, a C1-C6 alkyl group or a hydroxyl group, and a chemically amplified resist composition containing the same.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: April 17, 2012
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Ichiki Takemoto, Nobuo Ando
  • Patent number: 8143069
    Abstract: A compound represented by the following general formula (II): wherein R21 represents hydrogen atom or one to four monovalent substituents substituting on the benzene ring, and when R21 represents two or more substituents, the substituents may be the same or different; R22, R24, R25, and R27 independently represent hydrogen atom, or a monovalent substituent; R23 represents —OH or —N(R28)(R29) (wherein R28 and R29 independently represent an alkyl group which may be substituted); R26 represents —N(R30)(R31) (wherein R30 and R31 independently represent an alkyl group which may be substituted); n represents an integer of 1 to 3; and Y represents —S— or —O—, which is useful for selective measurement of hypochlorite ion.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: March 27, 2012
    Assignee: The University of Tokyo
    Inventors: Tetsuo Nagano, Yasuteru Urano, Suguru Kenmoku
  • Patent number: 8134146
    Abstract: The present invention relates to heterocyclic radicals or diradicals, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, to the use thereof to organic semiconductive materials and to electronic and optoelectronic components.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: March 13, 2012
    Assignee: Novaled AG
    Inventors: Michael Limmert, Olaf Zeika, Martin Ammann, Horst Hartmann, Ansgar Werner
  • Publication number: 20110020448
    Abstract: Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 27, 2011
    Applicants: MAZENCE, INC., KT & G CORPORATION
    Inventors: Myung-Gyu Park, Taehwan Kwak
  • Patent number: 7842822
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 30, 2010
    Assignee: Eli Lilly and Company
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Timothy Ivo Richardson
  • Patent number: 7842826
    Abstract: A process performs solid phase synthesis of halogenated derivatives of fluorescein, and includes reacting fluorescein with a halide MX, wherein M is an alkali metal and X is a halogen, and Oxone® (2 KHSO5.KHSO4.K2SO4), at a temperature higher than or equal to 150° C. A structure uses a halogenated derivative of fluorescein selected from the group consisting of 2?,4?,5?-trichlorofluorescein, 2?,4?,5?,7?-tetrachlorofluorescein, 4?,5?-diiodofluorescein diacetate and 2?,4?,5?-triiodofluorescein as electro-bistable material in a non-volatile memory device.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: November 30, 2010
    Assignee: STMicroelectronics S.r.l.
    Inventors: Maria Viviana Volpe, Angela Cimmino, Alessandro Pezzella, Aniello Palma
  • Patent number: 7632975
    Abstract: A process is provided for the synthesis of a compound of formula (I): wherein: M=0 or 1; N and p are 0 or 1 to 4; X is a single bond, O, S or NH; And R1-R4 are as defined in claim 1.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: December 15, 2009
    Assignee: CDT Oxford Limited
    Inventor: Sophie Heidenhain
  • Publication number: 20090298925
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Application
    Filed: July 31, 2009
    Publication date: December 3, 2009
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Patent number: 7585985
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: September 8, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Patent number: 7495111
    Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: February 24, 2009
    Assignee: Wyeth
    Inventors: P. Sivaramakrishnan Ramamoorthy, Zhongqi Shen, Boyd L. Harrison
  • Patent number: 7476741
    Abstract: The present invention is directed to substituted 4H-chromenes, 2H-chromenes, chromans and analogs thereof, represented by the general Formula (I) wherein R5, A, B, X, Y, Z and dotted lines are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: January 13, 2009
    Assignees: Cytovia, Inc., Shire BioChem, Inc.
    Inventors: Sui Xiong Cai, Songchun Jiang, Giorgio Attardo, Réal Denis, Richard Storer, Rabindra Rej
  • Publication number: 20080312312
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.
    Type: Application
    Filed: August 1, 2008
    Publication date: December 18, 2008
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Patent number: 7442812
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor ? agonists for treating Estrogen Receptor ? mediated diseases such as benign prostatic hyperplasia.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 28, 2008
    Assignee: Eli Lilly and Company
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Timothy Ivo Richardson
  • Patent number: 7405310
    Abstract: This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: July 29, 2008
    Assignee: Medivir AB
    Inventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
  • Patent number: 7354951
    Abstract: The present invention relates to novel benzopyran ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis. Formula (I), wherein G is —O—, —S(O)n, —CF2—, —C(O)—, —CR1H— or —CR2(OH)—; R is halo, (C1-C4)alkyl or R3—(CH2)m—; R1 is F, hydroxyl, cyano, trifluoromethyl, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkylcarbonyloxy or benzyl; R2 is trifluoromethyl or (C1-C4)alkyl; R3 is cyano, hydroxyl, (C2-C4)alkenyl, (C1-C4)alkoxy or (C1-C4)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 8, 2008
    Assignee: Eli Lilly and Company
    Inventors: Bryan Hurst Norman, Timothy Ivo Richardson
  • Patent number: 7332519
    Abstract: Spirocyclic cyclohexane compounds, methods for their production, pharmaceutical compositions containing these compounds, and the use of these spirocyclic cyclohexane compounds for treating conditions associated with the nociceptin/ORL1 receptor system, e.g. pain, drug withdrawal, anxiety, etc.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: February 19, 2008
    Assignee: Gruenenthal GmbH
    Inventors: Claudia Hinze, Bernd Sundermann, Stefan Oberboersch, Werner Englberger, Elmark Friderichs, Sven Frormann, Babette-Yvonne Koegel, Klaus Linz, Beatrix Merla, Derek Saunders, Wolfgang Schroeder, Hans Schick, Birgitta Henkel, Helmut Sonnenschein
  • Patent number: 7288560
    Abstract: The present invention relates to spirocyclic cyclohexane compounds, to methods for their production, to pharmaceutical compositions containing these compounds, to methods of treatment using such compounds and to the use of such spirocyclic cyclohexarie compounds for producing pharmaceutical compositions.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 30, 2007
    Assignee: Gruenenthal GmbH
    Inventors: Claudia Hinze, Bernd Sundermann, Hans Schick, Birgitta Henkel
  • Patent number: 7282246
    Abstract: Concerning the compound of the formula (I) R1, R3 are each independently, for example, H R2, R4 are each independently, for example, H X1, X2 are each independently H or F M1 is —CO—O—, —O—CO—, —CH2—O—, —O—CH2—, —CF2—O—, —O—CF2—, —CH?CH—, —CF?CF—, —C?C—, —CH2—CH2—CO—O—, —O—CO—CH2—CH2—, —CH2—CH2—, —CF2—CF2—, —(CH2)4—, —OC(?O)CF?CF— or a single bond A1 is, for example, 1,4-phenylene, and R5 has the same possible definitions as specified for R2 and R4, with the exception of —M1-A1-R5, but independently of the particular definitions of R2 and R4 with the following provisos: 1) at least one of X1, X2 has to be F 2) R1, R2, R3 and R4 must not at the same time be H 3) at most two of R1, R2, R3 and R4 may be c).
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: October 16, 2007
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Schmidt, Barbara Hornung, Rainer Wingen
  • Patent number: 7279499
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 9, 2007
    Assignee: Eli Lilly and Company
    Inventors: Gregory Lee Durst, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Patent number: 7268132
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: September 11, 2007
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo
  • Patent number: 7217734
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: May 15, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
  • Patent number: 7186850
    Abstract: The present invention relates to a process for the production of compound (A) comprising reacting compound (B) with compound (C). A further ring closure reaction may be necessary. The invention further relates to certain novel compounds of formula (B).
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: March 6, 2007
    Assignee: Johnson Matthey Public Limited Company
    Inventor: Lee Jonathan Silverberg
  • Patent number: 7160852
    Abstract: The compound according to the formula set forth below and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: January 9, 2007
    Assignee: International Flavors & Fragrances Inc
    Inventors: Anthony T. Levorse, Jr., Anubhav P. S. Narula, Edward Mark Arruda, Charles E. J. Beck
  • Patent number: 7105685
    Abstract: The invention provides cannabinol derivatives and pharmaceutical preparations thereof.
    Type: Grant
    Filed: December 22, 2002
    Date of Patent: September 12, 2006
    Inventor: Craig R. Travis
  • Patent number: 7019024
    Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: March 28, 2006
    Assignee: Allelix Neuroscience Inc.
    Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
  • Patent number: 6894177
    Abstract: Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)urea bond; R3 is H, C1-C3 alkyl, R4-R7 are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, haloC1-C6 alkyl, C1-C6 alkanoyl, haloC1-C6 alkanoyl, C1-C6 alkoxy, haloC1-C6 alkoxy, C1-C6 alkyloxy-C1-C6 alkyl, haloC1-C6 alkyloxy-C1-C6 alkyl hydroxy-C1-C6 alkyl, amino-C1-C6 alkyl, carboxy-C1-C6 alkyl, cyano-C1-C6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto; X is —(CH2)n?—D—(CH2)m—; D is —O—, —S—; n and m are independently 0 or 1; and prodrugs and pharmaceutically acceptable salts thereof, have utility as inhibitors of HIV-1 reverse transcriptase, particularly drug escape mutants.
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: May 17, 2005
    Assignee: Medivir AB
    Inventors: Stefan Lindström, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Odén, Lotta Naeslund
  • Patent number: 6887533
    Abstract: Compounds of the formula (I) where: X1 is H or F G1-G2 is —CH2—CH— or CH?C— R1, R2 are a) H b) the M2-A2-R5 moiety c) for example, a straight-chain or branched alkyl radical having from 1 to 16 carbon atoms R3 and R4 are each, for example, H, the M2-A2-R5 moiety or a straight-chain or branched alkyl or alkyloxy radical having from 1 to 16 carbon atoms A2 is, for example, 1,4-phenylene, with the provisos that a) when R2 is not H, R1 and R3 have to be H, b) when R2 is H, R4 must not have the definitions c) or d), c) R1, R2, R3 and R4 must not at the same time be H.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: May 3, 2005
    Assignee: Clariant International, Ltd.
    Inventors: Wolfgang Schmidt, Barbara Hornung, Rainer Wingen
  • Patent number: 6869696
    Abstract: The invention concerns an electro-luminescent device in which the luminescent layer contains a compound of general formula I as doping agent or as luminescent compound, whereby the radicals R1 to R12 are identical or are different, and mean hydrogen, straight chain or branched C1-C6 alkyl, aralkyl, aryl or substituted aryl; R1 and R2 and/or R3 and R4 and/or R4 and R5 and/or R5 and R11 and/or R8 and R5 and/or R4 and R12 can form an alicyclic, heterocyclic or aromatic ring; R5 can furthermore be H, OH, OR9, N,N-di-(C1-C6) alkylamino, acetylamino or halogen; R6 and R7 together can form an alicyclic or heterocyclic ring; A1 and A2 are identical or different and are —CN, —NO2 or —COOR8; X is —CH, —CR11 or N; and Y is O, —NH, —NR12, S or Se. The doping agents together luminesce predominately red with very good quantum efficiency together with the luminescent compound as a function of concentration.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: March 22, 2005
    Assignee: Sensient Imaging Technologies GmbH
    Inventors: Andreas Richter, Dietmar Keil, Gerhard Diener
  • Patent number: 6849746
    Abstract: A process is disclosed for the production of polyphenol oligomers having n polyphenol monomeric units, n being an integer from 2-18. The process includes coupling of a protected polyphenol, having protected phenolic hydroxyl groups, with a C-4 functionalized polyphenol monomer. The protected polyphenol may be a protected polyphenol monomer or a protected polyphenol oligomer having 2-17 monomeric units. Advantageously, polyphenol monomeric units forming the polyphenol oligomers may be the same or different flavanoid compounds.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: February 1, 2005
    Assignee: Mars, Inc.
    Inventors: Leo J. Romanczyk, Jr., Alan P. Kozikowski, Werner Tueckmantel, Marc E. Lippman
  • Publication number: 20040171670
    Abstract: Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: March 9, 2004
    Publication date: September 2, 2004
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Alan L. Mueller, Scott T. Moe
  • Publication number: 20040167151
    Abstract: Compounds are described having a structure according to Formula I or Formula II: 1
    Type: Application
    Filed: February 24, 2003
    Publication date: August 26, 2004
    Inventors: Kuo-Hsiung Lee, Yi Xia, Zheng-Yu Yang, Kenneth F. Bastow, Sheng-Chu Kuo
  • Patent number: 6713622
    Abstract: A set of 4,7-dichlororhodamine compounds useful as fluorescent dyes are disclosed having the structures wherein R1-R6 are hydrogen, fluorine, chlorine, lower alkyl, lower alkene, lower alkyne, sulfonate, sulfone, amino, amido, nitrile, lower alkoxy, linking group, or, when taken together, R1 and R6 is benzo, or, when taken together, R4 and R5 is benzo; R7-R10, R12-R16 and R18 may be hydrogen, fluorine, chlorine, lower alkyl, lower alkene, lower alkyne, sulfonate, sulfone, amino, amido, nitrile, lower alkoxy, linking group; R11 and R17 may be hydrogen, lower alkyl, lower alkene, lower alkyne, phenyl, aryl, linking group; Y1-Y4 are hydrogen, lower alkyl, or cycloalkyl, or, when taken together, Y1 and R2, Y2 and R1 Y3 and R3, and/or Y4 and R4 is propano, ethano, or substituted forms thereof, and X1-X3 taken separately are hydrogen, chlorine, fluorine, lower alkyl, carboxylate, sulfonate, hydroxymethyl, and linking group, or any combinations thereof In another aspect, the invention includes reag
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: March 30, 2004
    Assignee: Applera Corporation
    Inventor: Ronald J. Graham
  • Publication number: 20040030159
    Abstract: Compounds useful as surface coating agents, including compounds of the formula: 1
    Type: Application
    Filed: July 14, 2003
    Publication date: February 12, 2004
    Inventor: Dale G. Swan
  • Patent number: 6670358
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: December 30, 2003
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Publication number: 20030228486
    Abstract: The invention concerns an electro-luminescent device in which the luminescent layer contains a compound of general formula I as doping agent or as luminescent compound, whereby the radicals R1 to R12 are identical or are different, and mean hydrogen, straight chain or branched C1-C6 alkyl, aralkyl, aryl or substituted aryl; R1 and R2 and/or R3 and R4 and/or R4 and R5 and/or R5 and R11 and/or R8 and R5 and/or R4 and R12 can form an alicyclic, heterocyclic or aromatic ring; R5 can furthermore be H, OH, OR9, N,N-di-(C1-C6) alkylamino, acetylamino or halogen; R6 and R7 together can form an alicyclic or heterocyclic ring; A1 and A2 are identical or different and are -CN, -NO2 or -COOR8; X is -CH, -CR11 or N; and Y is O, -NH, -NR12, S or Se. The doping agents together luminesce predominately red with very good quantum efficiency together with the luminescent compound as a function of concentration.
    Type: Application
    Filed: May 10, 2002
    Publication date: December 11, 2003
    Applicant: SynTec Gesellschaft fuer Chemie und Technologie der Informationsaufzeichnung mbH
    Inventors: Andreas Richter , Dietmar Keil , Gerhard Diener
  • Patent number: 6632788
    Abstract: The compound according to the formula set forth below where A is B is or A and B together form the ring structure and X, R′ and R are independently H and CH3 and m=0 or 1. and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: October 14, 2003
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Anthony T. Levorse, Jr., Anubhav P.S. Narula, Edward Mark Arruda, Charles E.J. Beck
  • Patent number: 6630508
    Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &bgr; agonists. Such agonists are useful for treating Estrogen Receptor &bgr; mediated diseases such as prostate cancer.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: October 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer
  • Publication number: 20030187266
    Abstract: Compounds of the formula I: 1
    Type: Application
    Filed: February 28, 2003
    Publication date: October 2, 2003
    Applicant: Medivir AB
    Inventors: Stefan Lindstrom, Christer Sahlberg, Hans Wallberg, Genaidy Kalyanov, Lourdes Salvador Oden, Lotta Naeslund
  • Patent number: 6602903
    Abstract: The invention relates to compounds of formula (I): and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: August 5, 2003
    Assignee: Les Laboratories Servier
    Inventors: Gérald Guillaumet, Marie-Claude Viaud, Ahmed Mamai, Isabelle Charton, Pierre Renard, Caroline Bennejean, Béatrice Guardiola, Philippe Daubos
  • Publication number: 20030130515
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: January 2, 2003
    Publication date: July 10, 2003
    Inventors: Vidyasagar Vuligonda, Alan T. Johnson, Roshantha A. Chandraratna
  • Patent number: 6583166
    Abstract: The invention relates to triazole compounds of formula (I), in which R1, R2, A and B have the meanings given in the description. The compounds provided for in the invention have a high affinity for the dopamine-D3-receptor and can therefore be used for the treatment of diseases which respond to the influence of dopamine-D3-ligands.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: June 24, 2003
    Assignee: Abbott Laboratories
    Inventors: Dorothea Starck, Hans-Jörg Treiber, Liliane Unger, Barbara Neumann-Schultz, Kai Blumbach, Dietmar Schöbel
  • Publication number: 20030028019
    Abstract: A chromene compound which develops yellow to red color, a high color density and a little initial color and which, when used in combination with an existing photochromic compound that exhibits blue color so as to develop a neutral tint, maintains uniformity in the color tone at the time of developing color or fading color, or exhibits a very large color fading rate.
    Type: Application
    Filed: May 24, 2002
    Publication date: February 6, 2003
    Inventors: Junji Momoda, Shingo Matsuoka, Hironobu Nagou